IBCG
@IBCG_BladderCA
Followers
1K
Following
3K
Media
16
Statuses
2K
We (the IBCG, International Bladder Cancer Group) are a group who are devoted to positively affecting the care of bladder cancer patients globally.
Joined January 2016
It’s a wrap! Thanks to everyone who joined in person and online for turning this into a focused effort that was energizing, data driven, and genuinely worthwhile. @IBCG_BladderCA @SanRaffaeleMI @AndreaNecchi @SpiessPhilippe @PGrivasMDPhD @shilpaonc @CMercinelli @neerajaiims
A lot of intense discussions ongoing at @SanRaffaeleMI around biomarkers in GU cancers! @IBCG_BladderCA @GTumors @UroDocAsh @SpiessPhilippe
0
15
40
What a robust discussion it was with such a global panel in person and online. Lot of great thought provoking ideas generated to make us think how to answer important Qs and design future trials! Kudos @AndreaNecchi on leading this with @UroDocAsh @SpiessPhilippe @IBCG_BladderCA
A lot of intense discussions ongoing at @SanRaffaeleMI around biomarkers in GU cancers! @IBCG_BladderCA @GTumors @UroDocAsh @SpiessPhilippe
0
7
27
Elegant overview of BCG & IO advances in bladderca by @UroDocAsh at @SanRaffaeleMI urologic retreat 4th edition #GUReRetreat25 BCG is still the undisputed king in NMIBC. We need to think about pros & cons of adding IO to BCG upfront. @AndreaNecchi @IBCG_BladderCA
1
3
16
1
4
24
At @SanRaffaeleMI #GURetreat25 organized by @AndreaNecchi An outstanding overview of the @IBCG_BladderCA by the master President @UroDocAsh Remarkable work through last 2 decades defining intermediate risk NMIBC, clinical trial endpoints, consensus guidelines from IBCG retreats,
3
3
19
Terrific society overviews from @GTumors, @IBCG_BladderCA, @eaonc, @EORTC, @meeturoIT, @SWOG & @NRGonc from esteemed leaders from each group, incl @UroDocAsh, @SpiessPhilippe, @PGrivasMDPhD & @drjefstathiou. Well done @AndreaNecchi to put this superb group together in person.
0
5
25
Great options for patients who are ineligible for cisplatin-based chemotherapy diagnosed with MIBC. Important mile stone for perioperative treatment for MIBC! @BladderCancerUS @IBCG_BladderCA
fda.gov
On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex,
0
3
12
Do not miss our @IBCG_BladderCA @GTumors Consensus meeting on Liquid biomarkers in bladder and GU Cancers today, with a live streaming on YouTube @urotoday @OncoAlert @VJOncology @GUOncologyNow @UroDocAsh @SpiessPhilippe et al! https://t.co/sU2JndIxNK
0
9
22
🚨FDA approval of perioperative EV + pembrolizumab marks a major advance for cis-ineligible MIBC. KN905/EV303 showed OS/EFS benefits and unprecedented pCR rates in this population. @OncoAlert @OncoReporte @urotoday @myESMO @Larvol @IBCG_BladderCA
https://t.co/TFb90DUN0Y
fda.gov
On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex,
1
5
9
A lot of intense discussions ongoing at @SanRaffaeleMI around biomarkers in GU cancers! @IBCG_BladderCA @GTumors @UroDocAsh @SpiessPhilippe
2
12
41
Starts tomorrow! Join us live via YouTube channels: Nov 21: https://t.co/ls1kfQ7G1B Nov 22: https://t.co/ycVZXAgcv1
@AndreaNecchi @PGrivasMDPhD @montypal @neerajaiims @shilpaonc @SpiessPhilippe @IBCG_BladderCA @AmirHorowitz @UrogerliMD @spsutkaMD @mouwlab @pjhensley11
We have almost arrived…1 week left! @SanRaffaeleMI #GURetreat25 @IBCG_BladderCA @GTumors November 21-22 Milan, IT & live stream on YouTube channel @urotoday @OncoAlert @VJOncology @GUOncologyNow @UrologyTimes @Larvol
0
8
25
Disitamab-Vedotin plus Toripalimab showed similar clinical efficacy in metastatic urothelial cancer patients compared to EVP. ➡️ only in biomarker positive patients: Her2neu 1+-3+ ‼️ ➡️ ORR in phase 1/2 trial in Her2 negative (0) patients is 0%‼️ ( https://t.co/C8FfGlYJCs) -
🎉🔬 The 18th episode is out. Trastuzumab-Deruxtecan approved by FDA two days ago! Agnostic approval including bladder cancer 🚨‼️🎯 But only for Her2neu 3+ positive tumors! 👉 but what does 3+ actually mean? Similar to PD-L1 testing different assays and algorithms exist
0
11
22
@drenriquegrande Thanks for highlighting our paper Enrique. Bottom line: bladder preservation is a laudable goal and one that we are all committed to making a reality for patients. However it must be done safely and if one is going to forgo RC then other options (TMT) currently have more data
1
3
12
Out in @ESMO_Open @myESMO an important study led by @BrigidaMaiorano: Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study https://t.co/snTnJW2R2v
@UroDocAsh @SpiessPhilippe @montypal @neerajaiims
esmoopen.com
Several immune checkpoint inhibitors (ICIs) are approved for urothelial carcinoma (UC), but limited information is currently available regarding the efficacy of rechallenging ICIs in patients with...
1
23
48
@UroDocAsh @emanuele_crupi @AndreaNecchi @IBCG_BladderCA @EurUrolFocus @MaxKates @PGrivasMDPhD @shilpaonc @siadaneshmand @SpiessPhilippe @OAlhalabiMD @joanfundi @neerajaiims @LauraBukavinaMD @mouwlab Ready for primetime? cT0 is not pT0 MRI needs validation ctDNA negative in niagara not strongly related to pCR
0
3
9
The patient voice is critical in every part of #BladderCancer care. Grateful to Doug and Camille for sharing their journey so openly. Their insights add a depth we can’t capture any other way. @Medthority @IBCG_BladderCA @BladderCancerUS @WorldBladderCan @PGrivasMDPhD
How can you help patients and caregivers navigate the impacts of an #NMIBC diagnosis? Host @UroDocAsh talks to husband and wife Doug and Camille in the latest episode of Expert voices - Navigating NMIBC. Listen now for first-hand patient insights #MedX
https://t.co/tdFG9o0UCV
2
4
18
A remarkable milestone in 🇲🇽. Grateful to work alongside AMUO, SMU, CMUN and leaders from the country’s major institutions to shape the first national #bladdercancer guidelines. Nearly two years of effort, 40 experts, one shared mission – better care for patients. Thanks to
3
15
39
A remarkable milestone in 🇲🇽. Grateful to work alongside AMUO, SMU, CMUN and leaders from the country’s major institutions to shape the first national #bladdercancer guidelines. Nearly two years of effort, 40 experts, one shared mission – better care for patients. Thanks to
0
2
10
Congrats @UroDocAsh on your leadership of @IBCG_BladderCA in expanding the footprint to 🇲🇽
A remarkable milestone in 🇲🇽. Grateful to work alongside AMUO, SMU, CMUN and leaders from the country’s major institutions to shape the first national #bladdercancer guidelines. Nearly two years of effort, 40 experts, one shared mission – better care for patients. Thanks to
1
3
8
Thank you dear @chadinabhan for shedding light on the problem of disparities across the globe regarding access to drugs and clinical trials Enjoyed the podcast with you @IBCG_BladderCA @GTumors
How can we take scientific data presented at major meetings like @ASCO & @myESMO and assure it’s translatable to LMIC that have fewer resources? The inspiring @karima_oualla explains how she brings innovation & research to Morocco as an example. Full video soon @PGrivasMDPhD
0
1
6